Need Customized global blood plasma market Study?
cbd nutraceuticals market

Blood Plasma Market Share, Size, Trends, Industry Analysis Report, By Application (Hemophilia, Hypogammaglobulinemia, Immunodeficiency Diseases, Von Willebrand’s Disease, Others); By Type; By End-Use; By Region; Segment Forecast, 2022 - 2030

  • Published Date:Jun-2022
  • Pages: 101
  • Format: PDF
  • Report ID: PM1311
  • Base Year: 2021
  • Historical Data: 2018 - 2020

Report Summary

The global blood plasma market was valued at USD 32.33 billion in 2021 and is expected to grow at a CAGR of 6.8% during the forecast period. Key factors responsible for the market growth increase in patients suffering from severe blood disorders such as Hemophilia, Thalassemia, and others. As per the statistics published by the CDC, in 2020, each year, around 400 babies are born with the condition of Hemophilia A.

Blood Plasma Market Size
Know more about this report: Request for sample pages

Further, rising medical services consumption and expansion in immunodeficiency sicknesses are assessed to help the development of the industry. Furthermore, rising government drives for blood plasma and expanded mindfulness among individuals are driving the development of the market. Factors, for example, rising interest in the innovative work, development of medical services areas, developing pace of geriatric populace, and expanding reception of blood plasma inferred items are expected to raise the pieces of the pie.

The COVID-19 episode is expected to decidedly affect the development of the worldwide blood plasma subsidiaries market. The COVID-19 pandemic has pushed medical services frameworks on the planet. In the meantime, in August 2020, the Food and Drug Administration (FDA) gave an Emergency Use Authorization (EUA) for gaining strength blood plasma for the treatment of hospitalized patients with COVID-19. The antibodies are gathered from contributors who have recuperated from COVID-19.

Blood Plasma Market
Know more about this report: Request for sample pages

Industry Dynamics

Growth Drivers
The expansion in the number of endorsements for blood plasma drives the development of the industry. Furthermore, a flood in the number of clinical examinations for assessing security and proficiency of a wide scope of restorative medications is expected to contribute to the development of the global market.

As indicated by the diary of BMC Infectious Disease, in November 2021, it was accounted for that the healing plasma treatment is utilized for the patient contaminated with the COVID-19. The Meta - investigation clinical preliminary is led to breaking down the proficiency and adequacy of recuperating blood plasma. The outcome shows the decline in the death rate in COVID-19 patients by gaining strength in blood plasma treatment.

Besides, ascend in R&D exercises to foster high-level blood plasma inferred items is supposed to give gainful open doors to the extension of the worldwide market during the conjecture time frame. In addition, the presence of key assembling organizations to make and disperse vital fluid items and ascend in consumption of medical care items move the development of the industry.

Drives have been taken by the government and confidential associations to foster the drug industry and push the development of the industry. In any case, the secondary effects caused because of the purpose of blood plasma, for example, unfavorably susceptible conditions, dazedness, quick pulses, and brevity in breath, are supposed to confine the blood plasma market development during the figure time frame.

Report Segmentation

The market is primarily segmented based on the type, application, end-use, and regions.

By Type

By Application

By End-Use

By Region

  • Albumin
  • Factor VIII
  • Factor IX
  • Immunoglobulin
  • Hyperimmune Globulin
  • Others

 

  • Hemophilia
  • Hypogammaglobulinemia
  • Immunodeficiency Diseases
  • Von Willebrand’s Disease
  • Others
  • Hospitals
  • Clinics
  • Others
  • North America (U.S., Canada)
  • Europe (France, Germany, UK, Italy, Netherlands, Spain, Russia)
  • Asia Pacific (Japan, China, India, Malaysia, Indonesia, South Korea)
  • Latin America (Brazil, Mexico, Argentina)
  • Middle East & Africa (Saudi Arabia, UAE, Israel, South Africa)

Know more about this report: Request for sample pages

Insight by Type

By type, the immunoglobulin portion ruled the market in 2021, and this pattern is supposed to go on during the gauge time frame, inferable from headways in R&D exercises in the medical care area and expansion in the predominance of safe, lacking issues. Nonetheless, the egg whites' fragment is supposed to observe impressive development during the conjecture time frame because of expansion in egg whites item use for non-restorative application and ascend in the reception of white egg items.

Insight by Application

By application, the other application fragment was the significant benefactor in 2021 and is supposed to keep up with its lead during the conjecture time frame, attributable to increment in the commonness of irresistible infection and expansion popular for blood plasma determined items.

In any case, the immunodeficiency infections fragment is supposed to observe significant development during the conjecture time frame, inferable from ascending in the predominance of safety issues and development in medical services use.

Insight by End-Use

Based on the end-use, the hospitals fragment dominated the market in 2021, and this pattern is supposed to go on during the conjecture time frame, attributable to increment in the predominance of the constant and irresistible, for example, immunodeficiency turmoil, hemophilia, and drive taken by the government and confidential association to foster development medical care area. Nonetheless, the center portion is supposed to observe extensive development during the estimated time frame, attributable to an increment in the number of facility areas.

Geographic Overview

North America collected a significant offer in the global blood plasma market in 2021. The huge portion of North America in the worldwide market is credited to the rising utilization of immunoglobulins in neurological and immune system infections and the rising utilization of prophylactic medicines among analyzed patients. A large number of enlisted hemophilic patients likewise drives the development of this market. The developing number of hemophilic patients will expand the reception of coagulation factors, which, thusly, will drive the growth in North America.

Asia Pacific is set to pick up speed through 2027, prompted by the higher purchaser family wages and the rising patient mindfulness in the locale. The flood in the number of R&D exercises and the rising government subsidizing will likewise add to the territorial development. Vital coordinated efforts that incorporate acquisitions, organizations, and consolidations alongside speculations, specialized movements, and novel item dispatches are a portion of the key procedures utilized by significant blood plasma market members to fortify their global position.

For example, in January 2019, "The Japanese Red Cross Society" marked an 8-year contract with Abbott to establish the organization as a select provider of immunoassay serological instrumentation and tests. On another occasion, in May 2020, the "European Blood Alliance (EBA)" combined efforts with the European Commission. This association assisted with working as well as dealing with an EU-wide, open-access stage that assembles information on the COVID-19 gaining strength plasma treatment.

Competitive Insight

Key players operating in the market include Bayer AG, Biotest, CSL limited, Fusion Health, Grifols, S.A, Kedrion Biopharma, LFB S.A, Octa Pharma, Sanofi, and Takeda. For instance, in March 2022, in collaboration with Swan Bitcoin and Spade Payment Solutions, OCTAPHARMA company LAUNCHEd PILOT across 32 locations that allow donors to be paid in bitcoin.

Blood Plasma Market Report Scope

Report Attributes

Details

Market size value in 2021

USD 32.33 Billion

Revenue forecast in 2030

USD 56.92 Billion

CAGR

6.8% from 2022 - 2030

Base year

2021

Historical data

2018 - 2020

Forecast period

2022 - 2030

Quantitative units

Revenue in USD Billion and CAGR from 2022 to 2030

Segments covered

By Type, By Application, By End-Use, By Region

Regional scope

North America, Europe, Asia Pacific, Latin America, Middle East & Africa

Key companies

Bayer AG, Biotest, CSL limited, Fusion Health, Grifols, S.A, Kedrion Biopharma, LFB S.A, Octa Pharma, Sanofi, and Takeda